CO7151499A2 - Formulación inyectable - Google Patents

Formulación inyectable

Info

Publication number
CO7151499A2
CO7151499A2 CO14255947A CO14255947A CO7151499A2 CO 7151499 A2 CO7151499 A2 CO 7151499A2 CO 14255947 A CO14255947 A CO 14255947A CO 14255947 A CO14255947 A CO 14255947A CO 7151499 A2 CO7151499 A2 CO 7151499A2
Authority
CO
Colombia
Prior art keywords
injectable formulation
injectable
formulation
nexde
pesta
Prior art date
Application number
CO14255947A
Other languages
English (en)
Inventor
Tetsuya Sato
Takuya Minowa
Yusuke Hoshika
Hidekazu Toyofuku
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49483139&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7151499(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of CO7151499A2 publication Critical patent/CO7151499A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

VER PESTAÑA DE ANEXOS
CO14255947A 2012-04-23 2014-11-21 Formulación inyectable CO7151499A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636932P 2012-04-23 2012-04-23
US201361791896P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CO7151499A2 true CO7151499A2 (es) 2014-12-29

Family

ID=49483139

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14255947A CO7151499A2 (es) 2012-04-23 2014-11-21 Formulación inyectable

Country Status (32)

Country Link
US (4) US20150086632A1 (es)
EP (1) EP2868318B2 (es)
JP (1) JP6249944B2 (es)
KR (1) KR102168263B1 (es)
CN (4) CN104363912A (es)
AR (1) AR090775A1 (es)
AU (1) AU2013253518B2 (es)
BR (1) BR112014026398B1 (es)
CA (1) CA2871398C (es)
CO (1) CO7151499A2 (es)
CY (1) CY1123195T1 (es)
DK (1) DK2868318T4 (es)
EA (1) EA026124B1 (es)
ES (1) ES2727454T5 (es)
HK (1) HK1205678A1 (es)
HR (1) HRP20190841T4 (es)
HU (1) HUE043686T2 (es)
IL (1) IL235211A0 (es)
IN (1) IN2014DN08870A (es)
JO (1) JO3524B1 (es)
LT (1) LT2868318T (es)
MX (1) MX361722B (es)
MY (1) MY169099A (es)
NZ (1) NZ630255A (es)
PH (1) PH12014502366B1 (es)
PL (1) PL2868318T5 (es)
PT (1) PT2868318T (es)
SG (2) SG10201608684QA (es)
SI (1) SI2868318T2 (es)
TW (1) TWI641395B (es)
UA (1) UA118084C2 (es)
WO (1) WO2013161830A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
WO2017106641A1 (en) * 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
WO2017134038A1 (en) 2016-02-01 2017-08-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
EP3500249A1 (en) 2016-08-16 2019-06-26 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
EP3577111A1 (en) 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Crystalline brexpiprazole
JPWO2021029020A1 (es) * 2019-08-13 2021-02-18
CN117794517A (zh) 2021-09-07 2024-03-29 四川科伦药物研究院有限公司 注射用布瑞哌唑长效制剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284202T3 (es) 1997-05-14 2007-11-01 Senju Pharmaceutical Co., Ltd. Preparaciones acuosas en suspension con excelente redispersabilidad.
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
JP5000835B2 (ja) * 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ES2315721T5 (es) * 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2007035348A2 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
CN101959519B (zh) * 2008-03-11 2013-03-20 爱尔康研究有限公司 用于玻璃体内注射的低粘度、高度絮凝的曲安奈德混悬液
NZ592984A (en) * 2008-11-19 2012-12-21 Merial Ltd Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
JP5575269B2 (ja) * 2010-08-24 2014-08-20 大塚製薬株式会社 カルボスチリル誘導体並びにシリコーンオイル及び／又はシリコーンオイル誘導体を含有する懸濁液及びケーキ組成物
CN103249416B (zh) * 2010-10-18 2019-06-04 大日本住友制药株式会社 注射用缓释制剂
IL296695A (en) * 2011-03-18 2022-11-01 Alkermes Pharma Ireland Ltd Pharmaceutical preparations containing sorbitan esters
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
JP6333802B2 (ja) * 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
TWI562991B (en) † 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
CA2871398A1 (en) 2013-10-31
CA2871398C (en) 2021-04-27
PH12014502366A1 (en) 2015-01-12
PL2868318T5 (pl) 2022-06-20
AR090775A1 (es) 2014-12-03
US10624889B2 (en) 2020-04-21
AU2013253518A1 (en) 2014-11-06
CN104363912A (zh) 2015-02-18
KR102168263B1 (ko) 2020-10-21
SI2868318T2 (sl) 2022-04-29
MX361722B (es) 2018-12-14
ES2727454T3 (es) 2019-10-16
EA201491937A1 (ru) 2015-03-31
US20200163960A1 (en) 2020-05-28
HK1205678A1 (en) 2015-12-24
KR20150003336A (ko) 2015-01-08
MY169099A (en) 2019-02-18
UA118084C2 (uk) 2018-11-26
US20180092910A1 (en) 2018-04-05
EA026124B1 (ru) 2017-03-31
JPWO2013161830A1 (ja) 2015-12-24
PH12014502366B1 (en) 2015-01-12
PT2868318T (pt) 2019-06-07
JP6249944B2 (ja) 2017-12-20
JO3524B1 (ar) 2020-07-05
SI2868318T1 (sl) 2019-06-28
AU2013253518B2 (en) 2017-10-05
HRP20190841T1 (hr) 2019-07-26
NZ630255A (en) 2016-05-27
BR112014026398A2 (pt) 2017-06-27
IL235211A0 (en) 2014-12-31
DK2868318T3 (da) 2019-06-03
LT2868318T (lt) 2019-07-25
TW201406401A (zh) 2014-02-16
US20220305007A1 (en) 2022-09-29
DK2868318T4 (da) 2022-03-28
CN111888329A (zh) 2020-11-06
ES2727454T5 (es) 2022-05-13
CY1123195T1 (el) 2021-10-29
WO2013161830A1 (ja) 2013-10-31
CN107536802A (zh) 2018-01-05
US20150086632A1 (en) 2015-03-26
HUE043686T2 (hu) 2019-09-30
IN2014DN08870A (es) 2015-05-22
EP2868318A1 (en) 2015-05-06
BR112014026398B1 (pt) 2022-11-29
MX2014012734A (es) 2015-04-10
TWI641395B (zh) 2018-11-21
HRP20190841T4 (hr) 2022-03-04
PL2868318T3 (pl) 2019-09-30
EP2868318B2 (en) 2022-01-26
CN110638752A (zh) 2020-01-03
EP2868318B1 (en) 2019-03-06
SG11201406775UA (en) 2014-12-30
EP2868318A4 (en) 2015-12-09
SG10201608684QA (en) 2016-12-29

Similar Documents

Publication Publication Date Title
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
CO7151499A2 (es) Formulación inyectable
CO7020912A2 (es) Inhibidores de bromodominios
CO7151521A2 (es) Anticuerpos anti-fcrn
CO7091177A2 (es) Inhibidores de la beta-secretasa
CO7151520A2 (es) Dispositivo de peluquería
CO7151511A2 (es) Derivado de cicloalcano
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
FR2997014B1 (fr) Composition sterile dermo-injectable
IN2014CN02639A (es)
BR112014023200A2 (pt) uso de uma composição
BR112014026926A2 (pt) uso terapêutico de produtos de semente de chardonnay
CO7151512A2 (es) Inhibidores del nampt
DK2841054T3 (da) Injicerbart præparat
BR112014029176A2 (pt) formulações injetáveis de aprepitante
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
BR112014003027A2 (pt) formulação herbicida melhorada
BR112015003294A2 (pt) caldeira de armazenamento
CO7020915A2 (es) Inhibidores de iap
BR112014026634A2 (pt) direcionador
CO7141434A2 (es) Nueva forma de dosificación formulación de abediterol
IN2013DE00266A (es)
BR112014027219A2 (pt) método
CO7200262A2 (es) Nueva dosificación y formulación
BR112015001072A2 (pt) misturas refrigerantes